The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening.

Autor: Nagarkar R; Surgical Oncology, HCG Manavta Cancer Centre, Nashik, Maharashtra, India., Gopichand M; Surgical Oncology, HealthCare Global Enterprises Limited, Vijayawada, India., Pal SK; Radiotherapy, Indoriv Clinical, Kolkata, India., Gupta A; Research and Development Section, PredOmix Technologies Private Limited, Gurugram, India.; Research and Development Section, PredOmix Health Sciences Private Limited, Singapore., Saquib NM; Research and Development Section, PredOmix Technologies Private Limited, Gurugram, India.; Research and Development Section, PredOmix Health Sciences Private Limited, Singapore., Sagar G; Research and Development Section, PredOmix Technologies Private Limited, Gurugram, India., Rao KVS; Research and Development Section, PredOmix Technologies Private Limited, Gurugram, India.; Research and Development Section, PredOmix Health Sciences Private Limited, Singapore., Siddiqui Z; Research and Development Section, PredOmix Technologies Private Limited, Gurugram, India.; Research and Development Section, PredOmix Health Sciences Private Limited, Singapore., Longkumer I; Biochemistry, North East Cancer Hospital and Research Institute, Guwahati, Assam, India.
Jazyk: angličtina
Zdroj: International journal of women's health [Int J Womens Health] 2024 Jan 03; Vol. 16, pp. 1-7. Date of Electronic Publication: 2024 Jan 03 (Print Publication: 2024).
DOI: 10.2147/IJWH.S444258
Abstrakt: We evaluated the potential relevance of our multi-cancer detection test, OncoVeryx-F, for ovarian cancer screening. For this, we compared its accuracy with that of CA125-based screening. We demonstrate here that, in contrast to CA125-based detection, OncoVeryx-F detected ovarian cancer with very high sensitivity and specificity. Importantly here, Stage I cancers too could be detected with an accuracy of >98%. Furthermore, again unlike CA 125, the detection accuracy of OncoVeryx-F remained comparable in both Caucasian and South Asian/Indian women. Thus, the robustness and accuracy of OncoVeryx-F, particularly for early-stage detection, underscores its potential utility for ovarian cancer screening.
Competing Interests: AG, GS, ZS, NMS and KVSR are fulltime employees of PredOmix Technologies Private Limited. KVSR is a cofounder and owns stock in both PredOmix Technologies Private Limited and PredOmix Health Sciences Pte. Ltd. AG, ZS, and NMS own stock in PredOmix Health Sciences Pte. Ltd. SP is one of the Principal Investigators in studies sponsored by Predomix Technologies. The work described in this report is included in an Indian Provisional Patent Application filing. Application No. 202311002270. The authors report no other conflicts of interest in this work.
(© 2024 Nagarkar et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje